SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed reduced risk for disease progression and death with the investigative combination.
The FINANCIAL — Roche on December 7 announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in ...
On April 10, 2025, Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a new bevacizumab biosimilar referencing Genentech’s ...
The single-center study evaluated patients across multiple cancers to understand the utilization, safety, and financial outcomes of bevacizumab-awwb vs reference bevavizumab. Across a variety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results